Gallacher Capital Management LLC Has $13.09 Million Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)

Gallacher Capital Management LLC boosted its stake in Cassava Sciences, Inc. (NASDAQ:SAVA) by 0.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 581,606 shares of the company’s stock after acquiring an additional 3,782 shares during the quarter. Cassava Sciences makes up about 7.3% of Gallacher Capital Management LLC’s investment portfolio, making the stock its 2nd biggest position. Gallacher Capital Management LLC’s holdings in Cassava Sciences were worth $13,092,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Montag A & Associates Inc. boosted its stake in Cassava Sciences by 50.0% during the third quarter. Montag A & Associates Inc. now owns 1,500 shares of the company’s stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Cassava Sciences by 4.7% in the third quarter. Teacher Retirement System of Texas now owns 11,269 shares of the company’s stock valued at $188,000 after buying an additional 509 shares in the last quarter. Raymond James & Associates lifted its stake in shares of Cassava Sciences by 0.8% in the fourth quarter. Raymond James & Associates now owns 74,097 shares of the company’s stock valued at $1,668,000 after buying an additional 565 shares in the last quarter. Swiss National Bank lifted its stake in shares of Cassava Sciences by 0.9% in the third quarter. Swiss National Bank now owns 87,200 shares of the company’s stock valued at $1,451,000 after buying an additional 800 shares in the last quarter. Finally, Byrne Asset Management LLC lifted its stake in shares of Cassava Sciences by 32.9% in the fourth quarter. Byrne Asset Management LLC now owns 3,350 shares of the company’s stock valued at $75,000 after buying an additional 830 shares in the last quarter. Institutional investors own 38.05% of the company’s stock.

Cassava Sciences Trading Down 0.0 %

Shares of SAVA traded down $0.01 during trading hours on Friday, reaching $22.05. 1,147,869 shares of the stock traded hands, compared to its average volume of 1,105,216. The stock has a fifty day simple moving average of $21.37 and a 200 day simple moving average of $20.53. Cassava Sciences, Inc. has a 52 week low of $12.32 and a 52 week high of $32.10. The company has a market cap of $953.66 million, a price-to-earnings ratio of -9.50 and a beta of -0.38.

Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). Analysts predict that Cassava Sciences, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $124.00 price objective on shares of Cassava Sciences in a research note on Tuesday, March 5th.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.